Cardiovascular Events Reduction: Bivalirudin or Heparin?

Bivalirudin or Heparin eventsThe MATRIX study did not find a clear advantage of bivalirudin over unfractioned heparin to reduce major adverse cardiovascular events (MACE) or net cardiovascular adverse events (NCAE) in patients undergoing acute coronary syndrome receiving PCI.

 

This new analyzis confirms there is no difference in ischemic and thrombotic events in patients with acute coronary syndrome with and without ST elevation segment.

 

Bivalirudin has shown in other studies a benefit in mortality but only for STEMI patients.

 

MATRIX outcomes were originally presented at ACC 2015, and this pre-specified substudy analyzing the differences between STEMI and NSTEMI syndromes was recently published by BMJ.

 

Outcomes from 4,010 STEMI and 3,203 NSTEMI patients were compared. The decision to add a glycoprotein IIb/IIIa inhibitor to the heparin was left to operators’ criteria, and it reached 30.7% of STEMI and 10.9% of NSTEMI patients.

 

Among STEMI patients, researchers observed a 5.9% MACE rate in the bivalirudin group vs. 6.5% in the heparin group, a difference of no statistical significance.

 

In NSTEMI patients, MACE rate was 15.9% for bivalirudin and 16.4% for heparin, which again has no statistical difference.

 

For NCAE end point, which is a combination of major bleeding and MACE components (death, MI or stroke), there were no differences between bivalirudin and heparin across the whole spectrum of ACS.

 

There was a reduction in bleeding with bivalirudin (as prior studies have shown) but there was no excess stent thrombosis in the first hours, which differs from prior studies, probably mainly due to the fact that its protocol let extend drug infusion to full doses for four hours and a minor dose up to six hours.

 

Conclusion

Bivalirudin, compared to heparin and provisional glycoprotein inhibitors, did not result in a reduction of cardiovascular adverse events or net clinical adverse events in patients with or without ST elevation AMI.

 

 

Original Title: Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX).

Reference: Leonardi S et al. BMJ. 2016; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...